• 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 82741.
  • 2
    Tracey EA, Supramaniam R. Cancer in New South Wales: incidence and mortality 2000 featuring projections for selected sites. NSW Cancer Registry, May 2002.
  • 3
    Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of the epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 1996; 5: 56775.
  • 4
    Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, Bartek J, Bosch FX. Aberrant p21CIP1/WAF1 protein accumulation in head-and-neck. Int J Cancer 1997; 74: 3839.
  • 5
    Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16: 1197206.
  • 6
    Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, Je J, Sidransky D. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 1999; 18: 35415.
  • 7
    Shin DM, Hittelman WN, Hong WK. Biomarkers in upper aerodigestive tract tumorigenesis: a review. Cancer Epidemiol Biomarkers Prev 1994; 3: 697709.
  • 8
    Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 14759.
  • 9
    Snijders PJ, Steenbergen RD, Top B, Scott SD, Meijer CJ, Walboomers JM. Analysis of p53 status in tonsillar carcinomas associated with human papillomavirus. J Gen Virol 1994; 75: 276975.
  • 10
    Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58: 513.
  • 11
    Wilczynski SP, Lin B, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 1998; 152: 14556.
  • 12
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 70920.
  • 13
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 287584.
  • 14
    Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse and survival. Int J Cancer 2000; 89: 3004.
  • 15
    Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP. American Joint Committee on Cancer Staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997. 345.
  • 16
    Pindbord JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin, New York: Springer, 1997. 112.
  • 17
    Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990; 82: 147784.
  • 18
    Shibata DK, Arnheim N, Martin WJ. Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J Exp Med 1988; 167: 22530.
  • 19
    de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 105762.
  • 20
    Boxman IL, Berkhout RJ, Mulder LH, Wolkers MC, Bouwes Bavinck JN, Vermeer BJ, ter Schegget J. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108: 7125.
  • 21
    Wieland U, Jurk S, Weienborn S, Krieg T, Pfister H, Ritzkowsky A. Erythroplasia of Queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol 2000; 115: 396401.
  • 22
    Rose BR, Thompson CH, Chantrill LA, Tattersall MH, Cossart YE. Prevalence and distribution of human papillomavirus type 16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality. Int J Cancer 1992; 52: 2258.
  • 23
    Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 17418.
  • 24
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 71948.
  • 25
    Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187220.
  • 26
    Kuo MY-P, Hsu H-Y, Kok S-H, Kuo R-C, Yang H, Hahn L-J, Chiang C-P. Prognostic role of p27Kip1 expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 2002; 38: 1728.
  • 27
    Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, Riethdorf L, Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1 and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001; 439: 5561.
  • 28
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc 1958; 53: 45781.
  • 29
    Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR. Human papilloma virus and p53 in Head and Neck Cancer: clinical correlates and survival. Clin Cancer Res 1996; 2: 75562.
  • 30
    Friesland S, Mellin H, Munck-Wikland E, Nilsson A, Lindholm J, Dalianis T, Lewensohn R. Human Papilloma Virus (HPV) and P53 Immunostaining in advanced tonsillar carcinoma—relation to radiotherapy response and survival. Anticancer Res 2001; 21: 52934.
  • 31
    Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. Cancer 1997; 79: 595604.
  • 32
    Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. Cancer 2001; 92: 80513.
  • 33
    Snijders PJF, Scholes AGM, Hart CA, Jones AS, Vaughan ED, Woolgar JA, Meijer CJ, Walboomers JMM, Field JK. Prevalence of mucosotrophic human papillomaviruses in squamous-cell carcinomas of the head and neck. Int J Cancer 1996; 66: 4649.
  • 34
    Cattani P, Hohaus S, Bellacosa A, Genuardi M, Cavallo S, Rovella V, Almadori G, Cadoni G, Galli J, Maurizi M, Fadda G, Neri G. Association between cyclin D1 (CCND1) gene amplification and human papillomavirus infection in human laryngeal squamous cell carcinoma. Clin Cancer Res 1998; 4: 25859.
  • 35
    Butz K, Geisen C, Ullmann A, Spitovsky D, Hoppe-Seyler F. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 1996; 68: 50613.
  • 36
    Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997; 11: 210111.
  • 37
    Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 330112.
  • 38
    Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P, Strauss M, Bartek J. DNA tumour virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994; 125: 62538.
  • 39
    Parry D, Bates S, Mann DJ, Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16ink4/mts1 tumour suppressor gene product. EMBO J 1995; 14: 50311.
  • 40
    Kudo Y, Takata T, Yasui W, Ogawa I, Miyauchi M, Takekoshi T, Tahara E, Nikai H. Reduced expression of cyclin-dependent kinase inhibitor p27kip1 is an indicator of malignant behaviour in oral squamous cell carcinoma. Cancer 1998; 83: 244755.
  • 41
    Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13: 232330.